Distinguishing between aplastic anemia(AA)and hypoblastic myelodysplastic syndrome(hMDS)with a low percentage of bone marrow(BM)blasts(<5%)can be difficult due to the overlap in clonality and a spectrum of genetic ...Distinguishing between aplastic anemia(AA)and hypoblastic myelodysplastic syndrome(hMDS)with a low percentage of bone marrow(BM)blasts(<5%)can be difficult due to the overlap in clonality and a spectrum of genetic alternations between the two subtypes of diseases.However,due to recent advances in DNA sequencing technology,both spectnim and frequency of mutations can be accurately determined and monitored by next-generation sequencing(NGS)at initial diagnosis and during immunosuppressive therapy(1ST)in patients with AA or hMDS.This improvement in acquiring a patient's genetic status and clonal evolution can provide more proper,precise,and on-time information to guide disease management,which is especially helpful in the absence of traditional morphologic/cytogenetic evidence.展开更多
In December 2019,highly infectious 2019 novel coronavirus disease(COVID-19)broke out in Wuhan,China.The pathogen was identified as 2019 novel coronavirus(2019-nCoV).[1]The 2019-nCoV had the capacity to cause systemati...In December 2019,highly infectious 2019 novel coronavirus disease(COVID-19)broke out in Wuhan,China.The pathogen was identified as 2019 novel coronavirus(2019-nCoV).[1]The 2019-nCoV had the capacity to cause systematic injury including renal injuries besides pneumonia.[2]Angiotensin-converting enzyme 2(ACE2)acts as a cell entry receptor for 2019-nCoV.[1]ACE2 expression was dominant in proximal tubules within the kidney.In this study,the clinical data from hospitalized patients were retrospectively analyzed at their admission to identify if there is any evidence of proximal tubule injury.展开更多
基金the National Natural Science Foundation of China(No.81470009).
文摘Distinguishing between aplastic anemia(AA)and hypoblastic myelodysplastic syndrome(hMDS)with a low percentage of bone marrow(BM)blasts(<5%)can be difficult due to the overlap in clonality and a spectrum of genetic alternations between the two subtypes of diseases.However,due to recent advances in DNA sequencing technology,both spectnim and frequency of mutations can be accurately determined and monitored by next-generation sequencing(NGS)at initial diagnosis and during immunosuppressive therapy(1ST)in patients with AA or hMDS.This improvement in acquiring a patient's genetic status and clonal evolution can provide more proper,precise,and on-time information to guide disease management,which is especially helpful in the absence of traditional morphologic/cytogenetic evidence.
文摘In December 2019,highly infectious 2019 novel coronavirus disease(COVID-19)broke out in Wuhan,China.The pathogen was identified as 2019 novel coronavirus(2019-nCoV).[1]The 2019-nCoV had the capacity to cause systematic injury including renal injuries besides pneumonia.[2]Angiotensin-converting enzyme 2(ACE2)acts as a cell entry receptor for 2019-nCoV.[1]ACE2 expression was dominant in proximal tubules within the kidney.In this study,the clinical data from hospitalized patients were retrospectively analyzed at their admission to identify if there is any evidence of proximal tubule injury.
